bioRxivMolecular BiologyPreprint
Fc-independent SARS-CoV-2 infection-enhancing antibodies decouple N-terminal and receptor-binding domains by cross-linking neighboring spikes
Floris J. van EerdeniD, Songling LiiD, Tina LusianyiD, Hendra Saputra IsmantoiD, Tohru TeradaiD, Christoph GerleiD, Kanako AkamatsuiD, Mika HiroseiD, Fuminori SugiharaiD, David Virya CheniD, Jun-ichi KishikawaiD, Takayuki KatoiD, Yafei LiuiD, Masato OkadaiD, Hisashi AraseiD, Daron M. StandleyiD
Abstract
Antibody dependent enhancement (ADE) is a serious concern in vaccine development. The canonical ADE pathways are dependent on the fragment crystallizable (Fc) region of the antibody. In SARS-CoV-2 several antibodies have been discovered that inflict ADE in vitro. These antibodies target the N-terminal domain (NTD) of the SARS-CoV-2 spike protein. We previously proposed that these NTD-targeting infection-enhancing antibodies (NIEAs) cross-link neighboring spike proteins via their NTDs, and that this results in a decoupling between the NTD and receptor binding domain (RBD), facilitating the "RBD down" to "up" transition. In this study we present a combination of molecular dynamics simulations and cryogenic electron microscopy data that, together, demonstrate that NIEAs are indeed able to cross-link neighboring SARS-CoV-2 spike proteins, and that this cross-linking results in a decoupling of the NTD and RBD domains. These findings provide support for an Fc region independent ADE pathway that is not only relevant for SARS-CoV-2 but also for other viruses of which the spike proteins undergo a conformational change upon host cell entry.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement
B. D. Quinlan, H. Mou, … M. Farzan·bioRxiv·Apr 10, 2020
- An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies
- Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
- Characteristics and functions of infection-enhancing antibodies to the N-terminal domain of SARS-CoV-2
R. I. Connor, M. I. Sakharkar, … P. F. Wright·bioRxiv·Sep 19, 2023
- The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN
- SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
A. E. Chaouat, H. Achdout, … O. Mandelboim·bioRxiv·Apr 18, 2021